| Autor: |
Marie DeWitt, Chanida Siripraparat, Donovan T. Maust, Amita Patel, Sandra S. Swantek, Maureen C. Nash |
| Rok vydání: |
2019 |
| Předmět: |
|
| Zdroj: |
The American Journal of Geriatric Psychiatry. 27:S5-S6 |
| ISSN: |
1064-7481 |
| DOI: |
10.1016/j.jagp.2019.01.141 |
| Popis: |
Despite advances in the neurosciences, we continue to struggle with the treatment of neuropsychiatric symptoms in persons with dementia. There are very limited available treatments that are FDA approved. Recent statements and regulations have made the treatment of some neuropsychiatric symptoms of dementia more challenging. Despite the known risks of antipsychotics, APA has issued the statement indicating that there are still specific clinical situations which their use may be clinically appropriate. Conversely, CMS regulations have increased scrutiny of the use of antipsychotic medications in the Long-Term Care setting. The best interest of the patient seems to have been minimized, making it more difficult for us as geriatric psychiatrists to provide appropriate treatment for our patients. Our panel will discuss the following 1. The current data from examining antipsychotic and other psychotropic use among residents in long-term care using a national sample of Medicare data from 2009-2014, specifically focusing on antipsychotics and mood stabilizers. 2. The current CMS regulation of psychotropic medications prescribing with an emphasis on antipsychotics medication in Long-Term Care 3. The current public perception of dementia care 4. How CMS regulations of psychotropic medications affect the treatment of psychiatric patients and dementia care in nursing homes. 5. What we, as geriatric psychiatrists, can do to participate in the policy change to improve our ability to provide appropriate care to our patients in the current climate. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
